Londamocitinib

Londamocitinib (AZD4604) is a potent and selective JAK1 inhibitor with IC50 at 0.54 nM. Londamocitinib has anti-inflammatory activity[1][2][3].

Product Specifications

CAS Number

[2241039-81-4]

Product Name Alternative

AZD4604; JAK1-IN-7

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

JAK

Type

Reference compound

Related Pathways

Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/londamocitinib.html

Purity

99.79

Solubility

DMSO : 71.43 mg/mL (ultrasonic)

Smiles

FC1=C(S(C)(=O)=O)C=CC=C1NC2=NC(C3=CNC4=C3C=CC=C4NC([C@@H](COC)N5CCN(C)CC5)=O)=C(F)C=N2

Molecular Formula

C28H31F2N7O4S

Molecular Weight

599.65

Precautions

H302, H315, H319, H335

References & Citations

[1]NILSSON, Karl, Magnus, et al. Jak1 selective inhibitors. WO2018134213A1.|[2]Nilsson M, et al. Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization. J Med Chem. 2023 Oct 12;66 (19) :13400-13415.|[3]Nilsson M, et al. Characterization of Selective and Potent JAK1 Inhibitors Intended for the Inhaled Treatment of Asthma. Drug Des Devel Ther. 2022 Aug 31;16:2901-2917.